TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05166239

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HAIC
Description: Hepatic arterial chemotherapy consisted of infusions of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib 1
Description: 12/8 mg (weight ≥ 60kg / \< 60 kg) of Lenvatinib once daily after HAIC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Inhibitors
Description: PD-1 inhibitors injection intravenously or percutaneously before 24h of HAIC every 4 week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib 2
Description: 12/8 mg (weight ≥ 60kg / \< 60 kg) of Lenvatinib once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PD-1 inhibitors 2
Description: PD-1 inhibitors injection intravenously or percutaneously every 4 week.
Study: NCT04698850

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept 40 MG/ML [Eylea]
Description: Patients will be receiving intravitreal aflibercept starting with 3 monthly doses and continuing with treat-and-extend regimen with minimal interval of 8 week and maximum interval of 16 week. Interval can be prolonged or shortened by 2 or 4 weeks based on the disease activity and BCVA..

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brolucizumab-Dbll 120 MG/ML [Beovu]
Description: Patients will be receiving intravitreal brolucizumab starting with 3 monthly doses followed by the treatment interval of 8 or 12 weeks based on the disease activity and BCVA.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab 6 MG/ML [Lucentis]
Description: Rescue therapy for patients with study drug related adverse events or with worsening of BCVA and OCT finding even on the shortest treatment interval when resistance to study drug is suspected.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 6 MG/ML [Lucentis]
Description: Rescue therapy for patients with study drug related adverse events or with worsening of BCVA and OCT finding even on the shortest treatment interval when resistance to study drug is suspected.
Study: NCT06142890

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No cooling (control)
Description: Participants are exposed to 31°C, 45% relative humidity for 8 hours without cooling intervention (control condition). Drinking water is available ad libitum. Participants remain in supine position with slight (\~20°) chest and head elevation (low-Fowlers position) throughout the duration of bed-rest exposure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cooling with ceiling fan
Description: Participants are exposed to 31°C, 45% relative humidity for 8 hours. Drinking water is available ad libitum. Participants remain in supine position with slight (\~20°) chest and head elevation (low-Fowlers position) throughout the duration of bed-rest exposure. Participants will remain under a commercially available ceiling fan generating a standard air flow throughout the duration of exposure.
Study: NCT05638321

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIMS
Description: sterile surgical device made of stainless steel and plastic, which is coupled to a rotating system. The surgical device consists of stainless steel micro trephine, covered by a small needle and rotating mechanism behind it. Mechanical rotation of the surgical device is achieved by the rotating system which is comprised of a 1) Controller which dictates the activation pulse duration and RPM, 2) a Motor, and 3) Footswitch.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIMS
Description: sterile surgical device made of stainless steel and plastic, which is coupled to a rotating system. The surgical device consists of stainless steel micro trephine, covered by a small needle and rotating mechanism behind it. Mechanical rotation of the surgical device is achieved by the rotating system which is comprised of a 1) Controller which dictates the activation pulse duration and RPM, 2) a Motor, and 3) Footswitch.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIMS
Description: sterile surgical device made of stainless steel and plastic, which is coupled to a rotating system. The surgical device consists of stainless steel micro trephine, covered by a small needle and rotating mechanism behind it. Mechanical rotation of the surgical device is achieved by the rotating system which is comprised of a 1) Controller which dictates the activation pulse duration and RPM, 2) a Motor, and 3) Footswitch.
Study: NCT05653895

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol
Description: Resveratrol

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol
Description: Resveratrol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Acetyl-L-Carnitin, L Arginine, Co-Q10
Description: Treatment of PCOS with combination of Acetyl-L-Carnitin, L Arginine, Co-Q10

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Acetyl-L-Carnitin, L Arginine, Co-Q10
Description: Treatment of PCOS with combination of Acetyl-L-Carnitin, L Arginine, Co-Q10
Study: NCT06475716

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-based guided programme Spring
Description: Spring is an online guided self-help programme based on the principles of trauma-focused cognitive behavioral therapy and consists of 8 steps designed for delivery over 8 weeks. The steps cover psychoeducation, grounding techniques, management of anxiety, behavioral activation, imaginal exposure, cognitive restructuring, in vivo exposure, and prevention of relapse. The user of the programme also receives up to 3 hours of therapist guidance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based guided programme Spring
Description: Spring is an online guided self-help programme based on the principles of trauma-focused cognitive behavioral therapy and consists of 8 steps designed for delivery over 8 weeks. The steps cover psychoeducation, grounding techniques, management of anxiety, behavioral activation, imaginal exposure, cognitive restructuring, in vivo exposure, and prevention of relapse. The user of the programme also receives up to 3 hours of therapist guidance.
Study: NCT04168489

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active rTMS
Description: (rTMS) is received preliminary approval because of its noninvasive and safe analgesic effect.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham rTMS
Description: The sham rTMS is inactive and similar to placebo effect.
Study: NCT05347147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Presendin
Description: Presendin is supplied as 2 parts, one vial consisting of a drug part (white or greyish white powder in a clear vial) and one pre-filled syringe containing the diluent part (colourless liquid). The drug part is suspended in the diluent part solution and administered SC as a suspension.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is supplied as 2 parts (visually identical to the Presendin vial and pre-filled diluent syringe). The drug part will exclude the active pharmaceutical ingredient (exenatide acetate) and the diluent part will be the same as the active treatment diluent. The drug part is suspended in the diluent part solution and administered SC as a suspension.
Study: NCT06273683

Intervention type: OTHER
Intervention: Hand-held bipolar energy instrument
Description: A bipolar energy instrument is used for complete salpingectomy at the time of cesarean delivery.

Intervention type: OTHER
Intervention: Traditional suture ligation
Description: Traditional suture ligation technique is used for complete salpingectomy at the time of cesarean delivery.
Study: NCT06089369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab (9 cycles)
Description: IV infusion of Sintilimab （200mg intravenously every 3 weeks for a total of 9 cycles）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab (18 cycles)
Description: IV infusion of Sintilimab （200mg intravenously every 3 weeks for a total of 18 cycles）

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active surveillance
Description: Active surveillance
Study: NCT04729400

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vacuum Myofascial Therapy device
Description: Therapeutic Percutaneous Electrolysis and Vacuum Myofascial Therapy device once week for four weeks associated with eccentric exercises devices at home.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy program
Description: The multimodal physical therapy program includes 10 sessions of ultrasound pulsatil therapy (US) and massage associated with eccentric exercises devices at home.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Percutaneous Electrolysis
Description: Therapeutic Percutaneous Electrolysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound pulsatil therapy (US) and massage
Description: ultrasound pulsatil therapy (US) and massage
Study: NCT05974423

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tylenol, Ibuprofen, and Oxycodone
Description: A script for these three medications will be provided

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tylenol and Ibuprofen only
Description: A script for only these two medications will be provided initially following surgery. Should the patient need stronger medication for adequate pain control, the on-call physician will provide a script for oxycodone
Study: NCT05675683

Intervention type: DRUG
Intervention: Capmatinib
Description: Patients receiving Capmatinib

Intervention type: DRUG
Intervention: Capmatinib
Description: Patients receiving Capmatinib
Study: NCT05280847

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: fascial plane injection using ultrasound and fluoroscopic guidance
Study: NCT05377073

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hatha Yoga
Description: Patients in the yoga group performed warm-up exercises for 10 minutes, standing, sitting and supine positions of Hatha yoga (30 minutes), and relaxation and breathing exercises (20 minutes). The program consisted of one weekly session for a total of eight weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching
Description: Patients in the stretching group performed warm-up activities (10 minutes), and analytic stretching exercises targeting the following muscles: sternocleidomastoid, splenius, trapeze, triceps, posterior shoulder capsule, paravertebralis, hamstrings, quadriceps, gastrocnemius, soleus and tibialis anterior (40 minutes). Two repetitions of 15 seconds of each stretch were performed, with a 15 seconds interval between repetitions. The sessions ended with diaphragmatic breathing exercises (10 minutes). The program consisted of one weekly session for a total of eight weeks.
Study: NCT05368454

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Diabetes Self-Management Education and Support (DSMES) Program
Description: An online program for Diabetes Self-Management, Education and Support (DSMES) that includes personal coaching by a certified Diabetes Care and Education Specialist (CDCES), tracking tools, and FreeStyle Libre CGMs, a wearable sensor with data scanning ability accessed through the smartphone app.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: All participants randomized to the standard of care/control arm will be asked to continue with their current care plan and care team for management of their diabetes.
Study: NCT05392933

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound guided piriformis muscle lidocaine injection
Description: Ultrasound guided piriformis muscle (piriformis syndrome) 5 ml %2 lidocaine injection
Study: NCT05891964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab Injection
Description: Injection Secukinumab 150mg subcutaneously will be administered at weeks 0, 1, 2, 3, 4, and then monthly for 5 months.
Study: NCT05150444

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive and physical exercise training
Description: 12 weeks (3 times a week): patients will cycle on an adapted ergometer during their dialysis procedure. The exercise program will be run by kinesiologists. Participants will start with 15 minutes of cycling and then gradually increase the time and intensity. After the physical exercise session, they will continue with cognitive training. This training will be done on a tablet computer on a CogniFit platform (\~30 minutes). The brain games on mentioned platform automatically adapt to individual cognitive abilities.
Study: NCT04690205

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: End of Life (EOL) Care at at Home
Description: Remote monitoring and home-based care designed for patients with advanced hematologic malignancies
Study: NCT06198140

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myofascial release and quick icing
Description: In experimental group the individuals will receive myofascial release and quick icing. Quick icing will be on ankle dorsiflexors by using ice pack in the target area. Quick icing will be applied for 10 minutes (time of application 10 seconds and a rest for 20 seconds). This treatment protocol will be 6 times/week for 4 weeks in the hospital setting. Mayofascial release will be given on the target ankle planterflexors. The subjects who will receive Myofascial Release will be positioned in prone with the treatment area exposed. The treatment will be applied by the therapist standing at the side of the patient. Then technique will be applied with different levels by following longitudinal movements according to subject's tolerance for duration of 3 minutes in each sitting. Patients will be given a rest time after each level in order to allow the tissue to soften. This treatment protocol will be 6 times/week for 4 weeks in the hospital setting.
Study: NCT06112587

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: strength training
Description: A targeted 8-week strength-training course was offered as an intervention in combination with ergonomics and posture corrections and recommendations
Study: NCT06198140

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: myofascial release
Description: In control group the individuals will receive only myofascial release on ankle planterflexors. The subjects who will receive Myofascial Release will be positioned in prone with the treatment area exposed. The treatment will be applied by the therapist standing at the side of the patient. Then technique will be applied with different levels by following longitudinal movements according to subject's tolerance for duration of 3 minutes in each sitting. Patients will be given a rest time after each level in order to allow the tissue to soften. This treatment protocol will be 6 times/week for 4 weeks in the hospital setting.
Study: NCT05037188

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose BCD-250 injection
Description: A recombinant viral vector AAV5-RBD-S vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose BCD-250 injection
Description: A recombinant viral vector AAV5-RBD-S vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose or high dose BCD-250 injection
Description: A recombinant viral vector AAV5-RBD-S vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose or high dose BCD-250 injection
Description: A recombinant viral vector AAV5-RBD-S vaccine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: Placebo injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: Placebo injection
Study: NCT06341803

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Individually Neuronavigated accelerated intermittent theta burst stimulation with Magpro X100
Description: MagproX 100 and Axilium Cobot with Localite camera
Study: NCT05699902

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PECs block during mastectomy
Description: The patients were randomised to receive a PECS block consisting of 30 ml of levobupivacaine 0.25% after induction of anaesthesia (PECS group) or a saline mock block (control group). The patients answered a 40-item QoR questionnaire (QoR-40) before and 1 day after breast cancer surgery. MAIN OUTCOME MEASURES

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham block
Description: Female undergone mastectomy and have received conventional analgesic methods
Study: NCT06310629

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Nasal Cannula
Description: High Flow Nasal Cannula
Study: NCT04676009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise arm :
Description: Patients will receive physical activity recommendations at inclusion.~At each treatment cure, patients will receive pre-exercise nutritional recommendations and an acute physical exercise prior to immunotherapy and chemotherapy. The acute physical exercise will last 35 minutes and will be intermittent and individualized based on the results obtained by the patient during an endurance test on a ergocyle performed prior to treatment.~3 blood sampling times (2 EDTAsx10 mL) will be specially added to the study and will take place before exercise (1), after exercise (2) and 12 hours after the start of treatment (3).~A nutritional assessment will be carried out during the first and last treatment cure.~They will also benefit a home walking program. These patients will have to wear an activity tracker tracker during all intervention (3 months).~They will have a phone follow-up every 10 days (± 3 days) after each treatment cure for the study duration.
Study: NCT05112341

Intervention type: RADIATION
Intervention: radiation therapy
Description: the patient first is simulated then delineation is done

Intervention type: RADIATION
Intervention: radiation therapy
Description: the patient first is simulated then delineation is done
Study: NCT06310629

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrinseque Health Non-Rebreathing Mask (IHNRM)
Description: Intrinseque Health Non-Rebreathing Mask (IHNRM)
Study: NCT05139147

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DAISe Thrombectomy System
Description: DAISe Thrombectomy System for mechanical thrombectomy
Study: NCT06461884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Percussions
Description: Group A: Percussions and diaphragmatic breathing exercise will be performed with 1 session a day for total 3 days in a week for 4 weeks
Study: NCT05918887

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NJOY ACE commercial e-cigarette
Description: The NJOY ACE is the commercial version of the Standardized Research E-Cigarette (SREC), which was developed by NIDA with NJOY for research purposes.~Nicotine pods:~* Sealed, pre-filled, non-refillable~* 1.9 mL e-liquid with 5% w/w nicotine~* Approx 300 (280-330) puffs/pod~Nicotine liquid characteristics:~* Volume of liquid per pod 1.9 mL~* Active (nicotine USP 5% wt/wt)~* Propylene Glycol USP \& Vegetable Glycerin USP - PG/VG Ratio 0.77~* Lactic Acid USP~Battery characteristics:~* USB Rechargeable~* Storage Capacity \~ 400 mAh~* Approx 200 (3s) puffs / charge~* 300 charge cycles to \> 80% initial capacity~* Time to full charge 75 - 85 min~* Voltage / Temperature settings not user adjustable
Study: NCT04609748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol Oil
Description: Cannabidiol oil will be given twice a day, in a dose of 33,6mg, applied orally. The therapy will last 15 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nimesulide
Description: Nimessulid will be given twice a day - 2x100mg, applied orally. The therapy will last 15 days.
Study: NCT04871815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium pyruvate nasal spray
Description: Subjects will use a sodium pyruvate nasal spray 3x daily for 7 days.
Study: NCT05720312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Patterned pulsed magnetic stimulation delivered using an electromagnet. We will use a MagVenture rTMS device and a Cool-B65 coil.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Patterned pulsed magnetic stimulation delivered using an electromagnet. We will use a MagVenture rTMS device and a Cool-B65 coil.
Study: NCT06461884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: , Diaphragmatic breathing exercise
Description: Group B: Diaphragmatic breathing exercise will be performed with 1 session a day for total 3 days in a week for 4 weeks
Study: NCT06380660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-86225106 tablet
Description: ACE-86225106 will be administered orally daily as a continuous regimen. Subjects will continue to receive study treatment until PD as judged by local investigator review, development of unacceptable toxicity, or withdrawal of consent.
Study: NCT04866914

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy for Insomnia
Description: ACT-I treatment group: Participants diagnosed with chronic insomnia will receive group treatment. The six sessions will be aimed at psychoeducation about sleep added to the therapeutic processes of acceptance, mindfulness, availability, values, defusion and commitment, used in ACT.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Active control group CBT-I: Participants diagnosed with chronic insomnia will receive treatment in a group. The six sessions will be aimed at cognitive-behavioral components, such as education and sleep hygiene, stimulus control, sleep restriction and demystification / restructuring of belief beliefs.
Study: NCT05356728

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thealoz Duo (combination of trehalose and hyaluronate) eye drop and Hyabak (hyaluronate) eye drop
Description: One of the eyes will be assigned to use Thealoz Duo while the other with Hyabak by using randomisation table

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thealoz Duo (combination of trehalose and hyaluronate) eye drop and Hyabak (hyaluronate) eye drop
Description: One of the eyes will be assigned to use Thealoz Duo while the other with Hyabak by using randomisation table
Study: NCT04649372

Intervention type: PROCEDURE
Group type: OTHER
Intervention: EndoVE
Description: On the day of the procedure, a review of any changes which occurred since the pre-study visit will be conducted. The patient will be placed under general anaesthesia or sedated before Bleomycin will be delivered intravenously. The patient will then be treated endoscopically with the EndoVE device. The EndoVE procedure should take no longer than 30 minutes.